Paclitaxel enhancer compounds
US9107955B2 · kind B2 · utility
0Cited by
40References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 25, 2010 |
| Grant date | Aug 18, 2015 |
| Priority date | — |
| Expiry date | Apr 17, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2601/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a compound represented by the Structural Formula (I): Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent.Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with Paclitaxel or an analog of Paclitaxel.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.